ST Pharm Co.,Ltd. (KOSDAQ:237690)
South Korea · Delayed Price · Currency is KRW 123,600
+4,400 (3.69%)
Jul 10, 2026, 3:30 PM KST
ST Pharm Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, ST Pharm stock has a consensus rating of "Strong Buy" and an average price target of ₩197,000. The average 1-year stock price forecast is 59.39% higher than the current stock price, while the lowest is ₩170,000 (+37.54%) and the highest is ₩210,000 (+69.90%).
Price Target: ₩197,000 (+59.39%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ST Pharm stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 4 | 5 | 7 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 9 | 11 | 10 |
Financial Forecast
Revenue This Year
416.38B
from 331.68B
Increased by 25.54%
Revenue Next Year
500.90B
from 416.38B
Increased by 20.30%
EPS This Year
3.39K
from 2.69K
Increased by 26.14%
EPS Next Year
4.44K
from 3.39K
Increased by 30.92%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 441.0B | ||
| Avg | 416.4B | ||
| Low | 402.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 33.0% | ||
| Avg | 25.5% | ||
| Low | 21.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4,048.00 | ||
| Avg | 3,390.55 | ||
| Low | 2,634.00 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 50.6% | ||
| Avg | 26.1% | ||
| Low | -2.0% |